Alzheimer's disease

Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?
Endpoints
Thu, 05/6/21 - 10:57 am
Biogen
aducanumab
Alzheimer's disease
drug pricing
ICER
Tetra's Alzheimer's Drug Improves Language, Learning in Fragile X Syndrome
BioSpace
Sat, 05/1/21 - 09:12 pm
Tetra Therapeutics
BPN14770
Fragile X syndrome
Alzheimer's disease
Lilly, citing FDA feedback, won't seek speedy approval of Alzheimer's drug
BioPharma Dive
Tue, 04/27/21 - 11:25 pm
Eli Lilly
Alzheimer's disease
donanemab
Biogen’s Alzheimer’s hopeful aducanumab faces ‘less than a coin flip’s chance’ of FDA approval: analysts
Fierce Pharma
Wed, 04/21/21 - 11:29 pm
Biogen
aducanumab
Alzheimer's disease
When Will Lecanemab be Available to Alzheimer’s Patients?
BioSpace
Tue, 04/20/21 - 11:11 pm
Eisai
lecanemab
BAN2401
Alzheimer's disease
A new market beckons for Alzheimer’s blood tests
EP Vantage
Mon, 04/19/21 - 11:12 am
Alzheimer's disease
diagnostics
donanemab
Eli Lilly
Biogen
Quanterix
FDA grew too close to Biogen during Alzheimer’s drug development, doctors say
Pharmaforum
Thu, 04/1/21 - 10:51 am
FDA
Biogen
drug development
aducanumab
Alzheimer's disease
FDA advisers reassert case against approval of Biogen's Alzheimer's drug
BioPharma Dive
Wed, 03/31/21 - 10:55 pm
Biogen
FDA
Alzheimer's disease
aducanumab
Biogen's Aducanumab: A Look at the Drug’s History and Recent Updates
BioSpace
Sat, 03/27/21 - 12:14 pm
Biogen
Eisai
aducanumab
Alzheimer's disease
Partner Therapeutics’ Leukine Shows Promise for Alzheimer’s in New Study
BioSpace
Wed, 03/24/21 - 11:18 pm
Partner Therapeutics
Leukine
clinical trials
Alzheimer's disease
Will Another Alzheimer's Disease Drug Bite the Dust After Lilly's Latest Results?
Motley Fool
Wed, 03/24/21 - 10:14 am
Eli Lilly
Alzheimer's disease
donanemab
Big pharma’s key catalysts in the second quarter
EP Vantage
Wed, 03/24/21 - 10:04 am
Biogen
Alzheimer's disease
aducanumab
Sanofi
breast cancer
FDA
Biogen outlines 10M-patient opportunity for Alzheimer's drug in US
Biopharma Reporter
Tue, 03/16/21 - 10:48 pm
Biogen
Alzheimer's disease
aducanumab
Lilly lays out 2-year plan to gain approval for Alzheimer's drug
BioPharma Dive
Tue, 03/16/21 - 12:04 am
Eli Lilly
donanemab
clinical trials
Alzheimer's disease
Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing
Motley Fool
Mon, 03/15/21 - 11:03 am
Eli Lilly
Alzheimer's disease
clinical trials
donanemab
Clinical Trial Begins For Gene Therapy To Treat Alzheimer’s Disease
Forbes
Fri, 03/12/21 - 10:33 am
gene therapy
UCSD
Alzheimer's disease
clinical trials
Lilly lines up its next shot at Alzheimer’s
EP Vantage
Thu, 03/11/21 - 10:39 am
Eli Lilly
donanemab
Alzheimer's disease
New Drug Approval Could Be on Horizon for Alzheimer’s after 17-Year Drought
BioSpace
Tue, 03/9/21 - 09:53 pm
Alzheon
Alzheimer's disease
ALZ-801
AI uncovers Eli Lilly's rheumatoid arthritis drug Olumiant as potential Alzheimer's treatment
Fierce Biotech
Mon, 03/8/21 - 10:42 am
Eli Lilly
olumiant
JAK inhibitors
artificial intelligence
Alzheimer's disease
Where Will Biogen Be in 5 Years?
Motley Fool
Tue, 02/23/21 - 10:40 am
Biogen
aducanumab
Alzheimer's disease

Pages